Drugs company Cerecor raises $6.8m from private backers for depression treatment.

Biopharamaceutical firm Cerecor has raised $6.8m in series A funding to support development of its neuroscience drugs.

The US-based company is licensing and commercialising small molecule D-Amino Acid Oxidase (DAAO) inhibitors which were originally developed at the Johns Hopkins Brain Science Institute. In addition, Cerecor is transferring depression treatment, CERC-301, from life sciences firm Merck. The latest round of funding will be used to complete the acquisition.

Cerecor has now raised $28.9m since its inception in 2011. In addition to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?